Ligand to buy UK biotech Vernaliss for $43 million
San Diego-based Ligand would acquire programmes in respiratory, oncology and CNS
Read MoreSan Diego-based Ligand would acquire programmes in respiratory, oncology and CNS
Read MoreFollowing an appeal the drug will now be available to treat ALL
Read MoreTakeda has committed $100 million, including the participation in the Series A financing, to Ambys
Read MoreLawsuits allege that the company falsely and misleadingly marketed the two drugs
Read MoreDiabetes segment stumbles but key brand report solid performance
Read More




PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
